Jason Bell

Jason Bell serves as a Contracting Officer responsible for managing complex procurements within the life sciences and biotechnology sectors. He plays a pivotal role in executing the agency’s acquisition strategy by ensuring compliance with federal procurement regulations while advancing mission-critical scientific and medical objectives. His portfolio primarily encompasses research and development contracts, manufacturing services, and technical support for biological and pharmaceutical products. Bell is known for his methodical approach to solicitation development, source selection, and contract administration, ensuring rigorous evaluation of technical proposals and cost realism in high-stakes acquisitions. While no specific contractor relationships are currently identifiable, Bell routinely engages with a diverse range of vendors including large prime contractors, mid-tier manufacturers, and specialized R&D firms with expertise in biologics and pharmaceutical formulation. His procurement patterns reflect a preference for performance-based contracting and firm-fixed-price mechanisms, fostering accountability and outcomes-driven delivery. He maintains a collaborative relationship with technical evaluators and program managers to align contractual requirements with scientific and regulatory standards. Bell’s contracting activity is entirely focused on open competition, with 100% of awards issued under no set-aside conditions. This reflects a strategic emphasis on maximizing competition and leveraging broad industry capacity rather than socioeconomic set-asides. While he does not prioritize 8(a), HUBZone, or SDVOSB programs, his process remains fully compliant with all small business participation requirements, ensuring eligible firms have equitable access to opportunities. His primary NAICS focus centers on Biological Product Manufacturing (325414) and Pharmaceutical Preparation Manufacturing (325412), each accounting for 40% of his portfolio, with an additional 20% dedicated to Research and Development in Biotechnology (541714). He procures advanced therapeutics, clinical-stage biologics, and preclinical R&D services, demonstrating deep familiarity with cGMP standards, FDA regulatory pathways, and biopharmaceutical innovation cycles.